United Therapeutics Corporation

11/29/2023 | Press release | Distributed by Public on 11/29/2023 05:04

Material Event - Form 8-K

Item 8.01. Other Events.

As of November 27, 2023, United Therapeutics Corporation entered into an amendment extending the term of its exclusive license agreement with Eli Lilly and Company ("Lilly") covering the U.S. marketing, promotion, and sale of Adcirca® (tadalafil) tablets through December 31, 2026. Under the agreement, Lilly granted United Therapeutics an exclusive license for the right to develop, market, promote, and commercialize Adcirca for the treatment of pulmonary hypertension in the United States. The agreement was previously set to expire on December 31, 2023. Other terms of the license agreement remain the same.

ADCIRCA is a registered trademark of Eli Lilly and Company.